This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Noven And Shire Recall 39 Lots Of ADHD Patches

NEW YORK (AP) ¿ Shire PLC announced a new recall of the attention deficit hyperactivity disorder patch Daytrana, saying 39 production lots would be pulled from the market because patients could have trouble taking off the protective liner from the patch.

Shire voluntarily recalled thousands of Daytrana patches, made by its partner Noven Pharmaceuticals Inc., in 2008 for the same reason. The companies said the patches are still safe to use, but Shire said the patches no longer meet release liner removal specifications.

The companies said there are enough Daytrana patches on the market to meet demand from patients.

Noven is working on solutions for the liner issue. The Miami-based company said it expected the recall, and its costs will be paid for with a $3.8 million reserve established in case of further recalls. It backed its 2009 profit forecast.

On Monday, Shire withdrew a marketing application for Daytrana in Europe. The Basingstoke, U.K., company decided to focus instead on Equasym, a similar drug it bought from UCB Pharma last month. European regulators had asked Shire to conduct another clinical study of Daytrana before they would approve it.

Both drugs have the same active ingredient: methylphenidate, which is also found in Ritalin, Concerta, and Shire's older drug Adderall.

Noven shares fell 5 cents to $9.65 Friday morning. Shire's U.S-traded shares fell 23 cents to $35.38.
Copyright 2009 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.19 -1.04%
FB $118.08 0.55%
GOOG $695.81 0.50%
TSLA $234.18 0.80%
YHOO $35.97 -0.11%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs